Heart Failure affects 6.5 million Americans and represents a substantial burden to health systems in terms of both costs and hospitalizations. Transthyretin Amyloid Cardiomyopathy (ATTR-CM) is a rare, fatal, and underdiagnosed disease that can lead to Heart Failure. Patients affected by ATTR-CM often go years without a proper diagnosis and may cycle through multiple physicians and systems. This webinar features an expert in ATTR-CM, Dr. Rodney Falk, Director of the Cardiac Amyloidosis program at Brigham and Women’s Hospital (Part of Harvard affiliated Partners Healthcare) who will discuss his system’s approach to accurately suspecting, diagnosing, and managing patients with ATTR-CM.